Progyny Inc (PGNY) Receives Overweight Rating from Barclays
Barclays initiates Overweight coverage on Progyny Inc (PGNY), highlighting growth potential.
Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 675 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. The company has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The firm provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. The company provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Progyny Inc.
Last Updated: Nov 19, 2025, 12:12 AM · Source: Finnhub.io
Barclays initiates Overweight coverage on Progyny Inc (PGNY), highlighting growth potential.
Insider Michael E. Sturmer sold 296,210 shares of Progyny Inc (PGNY) for $7.49 million.
Progyny Inc (PGNY) exceeds analyst expectations with Q3 2025 results.
Keybanc has upgraded Progyny Inc (PGNY) to Overweight from Sector Weight.